Medexus Pharmaceuticals Inc.
MDP.TOTSXHealthcare● Active
$3.95
+$0.04(+1.02%)
Market Cap$127586503
P/E Ratio—
52W High$4.17
52W Low$2.47
Medexus Pharmaceuticals Inc. (MDP.TO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MDP.TO · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.11B | $0.11B | $0.11B | $0.08B | $0.08B |
| Cost of Revenue | $0.05B | $0.05B | $0.05B | $0.04B | $0.04B |
| Gross Profit | $0.06B | $0.06B | $0.06B | $0.04B | $0.04B |
| Gross Margin %(computed) | 52.23% | 52.64% | 55.54% | 49.45% | 52.73% |
| Operating Expenses | |||||
| R&D Expenses | $0.01B | $0.01B | $0.00B | $0.01B | $0.00B |
| G&A Expenses | $0.03B | $0.03B | $0.04B | $0.03B | $0.02B |
| Total Operating Expenses | $0.05B | $0.05B | $0.05B | $0.05B | $0.04B |
| Operating Income | $0.01B | $0.01B | $0.01B | ($0.01B) | ($0.00B) |
| Operating Margin %(computed) | 7.59% | 9.55% | 7.04% | -16.14% | -1.73% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Income Before Tax | $0.00B | $0.00B | ($0.01B) | ($0.00B) | ($0.03B) |
| Income Tax Expense | ($0.00B) | $0.00B | ($0.01B) | ($0.00B) | ($0.00B) |
| Net Income | $0.00B | ($0.00B) | $0.00B | ($0.00B) | ($0.03B) |
| Net Margin %(computed) | 2.07% | -0.19% | 1.13% | -3.75% | -35.48% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.09 | $-0.01 | $0.08 | $-0.19 | $-1.86 |
| Wtd Avg Shares | 0.03B | 0.02B | 0.02B | 0.02B | 0.02B |
| EBITDA | $0.02B | $0.02B | $0.01B | $0.01B | ($0.02B) |
| EBITDA Margin %(computed) | 15.52% | 17.05% | 13.55% | 18.97% | -29.63% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Medexus Pharmaceuticals Inc. data
About Medexus Pharmaceuticals Inc. (MDP.TO) Income Statement
Medexus Pharmaceuticals Inc. (MDP.TO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, MDP.TO reported revenue of $0.11B, gross profit of $0.06B (gross margin 52.23%), and net income of $0.00B — a net profit margin of 2.07%.
Frequently asked questions
MDP.TO · 4 questionsMedexus Pharmaceuticals Inc. (MDP.TO) reported revenue of $0.11B for 2025, down 4.2% year-over-year.
MDP.TO revenueMDP.TO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08